

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Shaw, *et al.*

SERIAL NUMBER: 10/068,426

Examiner Haddad, Maher M.

FILING DATE: February 6, 2002

Art Unit 1644

FOR: PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Supplemental Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of cited references A8; B2-B4; and C9-C12; and
4. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 22058-503. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, No. 41,874
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-22410



30623

PATENT TRADEMARK OFFICE

THIS PAGE BLANK (USPTO)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Shaw, *et al.*
SERIAL NUMBER: 10/068,426 Examiner Haddad, Maher M.
FILING DATE: February 6, 2002 Art Unit 1644
FOR: PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF
USE THEREOF

BOX IDS
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 02 2003

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Supplemental Information Disclosure Statement is being filed within three months of the receipt of an International Search Report for PCT/US02/03549. Accordingly, no fee or certification is believed required. A copy of each of the references is enclosed unless otherwise indicated on the attached modified Form PTO-1449. Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 22058-503.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, No. 41,874
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-22410




30623

PATENT TRADEMARK OFFICE

THIS PAGE BLANK (USPTO)

Date of Deposit: March 28, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 02 2003

APPLICANTS: Shaw, *et al.*

SERIAL NUMBER: 10/068,426

Examiner Haddad, Maher M.

FILING DATE: February 6, 2002

Art Unit 1644

TECH CENTER 1600/2900

FOR: PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Supplemental Information Disclosure Statement is being filed within three months of the receipt of an International Search Report for PCT/US02/03549. Accordingly, no fee or certification is believed required. A copy of each of the references is enclosed unless otherwise indicated on the attached modified Form PTO-1449. Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 22058-503.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, No. 41,874
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-22410




30623

PATENT TRADEMARK OFFICE

THIS PAGE BLANK (USPTO)

RECEIVED

APR 02 2003



Please type a plus sign (+) in this box

+

TECH CENTER 1600/2900

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/068,426
	Filing Date	February 6, 2002
	First Named Inventor	Shaw
	Group Art Unit	1644
	Examiner Name	Haddad, Maher M.
	Attorney Docket Number	22058-503

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date mm/dd/yyyy	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate mm/dd/yyyy
	A8	5,593,959	01/14/1997	Miller, <i>et al.</i>			10/14/1993

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No	
	B2	EP	1 074 564	Ajinomoto Co., Inc.	02/07/2001.		
	B3	WO	98/08949	Genetics Inst.	03/05/1998		
	B4	WO	99/51642	Genentech, Inc.	10/14/1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C9	Cole, <i>et al.</i> 1997. "Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells." <i>Journal of Immunology</i> . 159(7):3613-3621.
	C10	Geneseq Online Database Accession Number: AAY49933. (02/01/2000).
	C11	Scalia, <i>et al.</i> 1999. "Effect of recombinant soluble p-selectin glycoprotein ligand-1 on leukocyte-endothelium interaction in vivo role in rat traumatic shock." <i>Circulation Research</i> . 84(1):93-102.
	C12	International Search Report for PCT/US02/03549. Mailed on January 27, 2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

THIS PAGE BLANK (USPTO)

RECEIVED

APR 02 2003

Please type a plus sign (+) in this box

+

TECHNICAL INFORMATION

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/068,426
	Filing Date	February 6, 2002
	First Named Inventor	Shaw
	Group Art Unit	1644
	Examiner Name	Haddad, Maher M.
	Attorney Docket Number	22058-503

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date mm/dd/yyyy	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate mm/dd/yyyy
	A8	5,593,959	01/14/1997	Miller, <i>et al.</i>			10/14/1993

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No	
	B2	EP	1 074 564	Ajinomoto Co., Inc.	02/07/2001		
	B3	WO	98/08949	Genetics Inst.	03/05/1998		
	B4	WO	99/51642	Genentech, Inc.	10/14/1999		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C9	Cole, <i>et al.</i> 1997. "Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells." <i>Journal of Immunology</i> . 159(7):3613-3621.
	C10	Geneseq Online Database Accession Number: AA49933 . (02/01/2000).
	C11	Scalia, <i>et al.</i> 1999. "Effect of recombinant soluble p-selectin glycoprotein ligand-1 on leukocyte-endothelium interaction in vivo role in rat traumatic shock." <i>Circulation Research</i> . 84(1):93-102.
	C12	International Search Report for PCT/US02/03549. Mailed on January 27, 2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

THIS PAGE BLANK (USPTO)